Upload
john-dockins
View
231
Download
0
Embed Size (px)
Citation preview
7/31/2019 Neoplastic Diseases of the Stomach
1/82
Neoplastic diseases of theStomach/Pancreas/Liver
John D. B. Dockins, MD
Friday Academic Session
12/17/10
7/31/2019 Neoplastic Diseases of the Stomach
2/82
Outline
Gastric Cancer
- Anatomy
- Overview
- Epidemiology
- Staging
- Surgery
- Combined ModalityTreatment
- Treatment Guidelines
- Summary
7/31/2019 Neoplastic Diseases of the Stomach
3/82
Anatomy
7/31/2019 Neoplastic Diseases of the Stomach
4/82
7/31/2019 Neoplastic Diseases of the Stomach
5/82
Anatomy
7/31/2019 Neoplastic Diseases of the Stomach
6/82
7/31/2019 Neoplastic Diseases of the Stomach
7/82
Overview
Cancers of UGITract- Stomach
- Esophagus- GE junction
Major HealthProblem Worldwide
2009 US Stats- 37,600 new cases- 25,150 deaths
7/31/2019 Neoplastic Diseases of the Stomach
8/82
Epidemiology
Rampant in Many Countries worldwide
- 4th most common Worldwide
- Japans most common cancer in men
Incidence declining since WWII
- One of least common in US
- 21,130 new cases 2009
- 10,620 eventual deaths 2009
Gastric Adenocarcinoma
- Cardiac origination dominates in West
- Non-cardiac/Distal dominates East (Japan, Korea, former USSR)
7/31/2019 Neoplastic Diseases of the Stomach
9/82
Epidemiology Often Dx at advanced stage
- Japan/Korea earlier detection ( screening)
Environmental risk factors
- H. Pylori
- Smoking
- High salt intake
- Dietary factors
Genetic factors
- Higher risk with family history
- 1-3% associated with inherited syndromes
- E-Cadherin mutations in 25% of a hereditary diffuse gastric cancer(genetic counseling recommended)
7/31/2019 Neoplastic Diseases of the Stomach
10/82
Staging 2 Major classifications
- Japanese (elaborate, anatomy, nodes)
- AJCC and UICC (Western Hemisphere)
- 15 LN recommended for adequate staging
Baseline Stage useful in tx strategy
- 50% present w/advanced disease (poor outcome)
- Poor performance status, mets., Alk Phos. > 100 U/L
Localized, resectable disease
- Outcome based on surgical stage
- 70-80% pts. have regional +LN mets. (# has profound influence onsurvival)
7/31/2019 Neoplastic Diseases of the Stomach
11/82
7/31/2019 Neoplastic Diseases of the Stomach
12/82
7/31/2019 Neoplastic Diseases of the Stomach
13/82
Pre-op Staging
Clinical staging has greatly improved with diagnosticmodalities
CT- routinely used (43-82%) sensitivity for T stage
PET-CT
- Lower detection rate than CT alone
- Lower sensitivity than CT for LN involvement (56%vs. 78%)
- Improved specificity (92% vs. 62%)
- higher accuracy in pre-op staging (68%) vs.CT(53%) or PET(47%)
PET not adequate as primary detection or stagingmodality
7/31/2019 Neoplastic Diseases of the Stomach
14/82
Pre-op Staging EUS
- assesses tumor depth
- T stage accuracy 65-92%
- N stage accuracy 50-95% (operator dependent)
- Distant nodal evaluation suboptimal
Laparoscopy
- Good for occult metastasis
- MSKCC study 657 staged laparascopically
- Metastatic dz. in 31% of patients
- Limitations were 2D evaluation and detecting hepatic mets. andperigastric LN
- Usually reserved for medically fit with resectable dz.
- May be used in unfit if there is consideration for adding radiation to chemo
7/31/2019 Neoplastic Diseases of the Stomach
15/82
Pre-op Staging
Cytogeneticanalysis
- Reports suggest(+) peritonealcytology is anindependent
predictor for riskof recurrencefollowing curativeresection
7/31/2019 Neoplastic Diseases of the Stomach
16/82
Surgery
Primary treatment forearly stage gastriccancer is surgery
Standard goal iscomplete resectionwith adequate margins(4cm or greater)
Type of resection
(subtotal vs. total) andextent oflymphadenectomy iscontroversial
7/31/2019 Neoplastic Diseases of the Stomach
17/82
Surgery
Primary goal is to accomplish complete resection with (-) margins(R0)
- R1 microscopic residual dz.
- R2 - macroscopic residual dz.
- 50% reach R0 resection of primary lesion
Subtotal gastrectomy is preferred approach for distal gastriccancers
- Similar outcome as total gastrectomy
- Significantly fewer complications
Proximal or total gastrectomy both indicated for proximalgastric cancer
- associated with post-op nutritional impairment
7/31/2019 Neoplastic Diseases of the Stomach
18/82
Surgery
Clinical Staging with CT +/- EUS is done pre-op
T1b- T3 tumors distal, total, or subtotal gastrectomy
T4 tumors- en-block resection of involved structures
Routine splenectomy should be avoided
- Slightly morbidity and mortality in pts. undergoing totalgastrectomy + splenectomy vs. total gastrectomy
- Marginal survival benefit
- Studies do not support prophylactic splenectomy to removemacroscopically negative LN
Placement of feeding jejunostomy considered for those receivingpost-op chemoradiation
7/31/2019 Neoplastic Diseases of the Stomach
19/82
Surgery
Unresectable disease
- Peritoneal involvement
- Distant metastasis
- Locally advanced disease (involvement or encasement of majorblood vessels)
Limitedgastric resection is acceptable for symptomaticpalliation of bleeding (+ margins acceptable)
Palliative gastric resection should not be performed unless pt. issymptomatic and LN dissection not required
Gastric bypass with gastrojejunostomy to proximal stomachused for palliation of symptomatic obstruction
Feeding jejunostomy or venting gastrotomy may also beconsidered
7/31/2019 Neoplastic Diseases of the Stomach
20/82
Surgery
LN dissection Controversial
Nodal stations defined
in proximity tostomach
- D0 no effort toresect LN (palliative)
- D1 perigastric LN
- D2 LN along maintunks of celiac axis
7/31/2019 Neoplastic Diseases of the Stomach
21/82
Surgery
Japanese surgeons advocate D2 LN dissection
- report overall survival
Several Western trial have investigated D2 LN dissection onoutcome
British Medical Group
- D2 vs D1 LN dissection- postop morbidity- no benefit in overall survival or recurrence free survival
Dutch Group- D1 vs D2 LN dissection (Japanese instructor)- no benefit in overall survival
Both trials incorporated distal pancreatectomy and splenectomy- Probably influenced long-term mortality
7/31/2019 Neoplastic Diseases of the Stomach
22/82
Surgery
Retrospective analysis comparing D2 vs D1 withoutpancreaticosplenectomy demostrate favorable survivalin D2 group
Benefit of aggressive lymphadenectomy is more
accurate staging
MSKCC- number of LN, not location is important in prognosis- N1 1-6 LN- N2 7-15 LN
- N3 - > 15 LN- 15+ LN improve prognostication and outcome
Likely due to improved staging (dont erroneously pts.With occult metastasis
7/31/2019 Neoplastic Diseases of the Stomach
23/82
Surgery
Endoscopic Mucosal Resection (EMR)- Major advance in endoscopic surgery- used for Tis or T1a tumors- require limited resection (5yr survival>90%)- Limited in US
Indications- well or moderately differentiated tumors- no ulceration- no invasive findings- tumors
7/31/2019 Neoplastic Diseases of the Stomach
24/82
Surgery
Laparascopic resection offers advantages- blood loss- pain and hospitalization- recovery- return of bowel funtion
Hulscher and colleagues- open vs. laparascopic subtotal gastrectomy- 59 pts.- Mortality 3.3 vs 6.7- 5yr OS rates 59.8 vs 55.7
- DFS 57.3 vs 54.8
Not statistically significant
More trials needed
7/31/2019 Neoplastic Diseases of the Stomach
25/82
Combined Modality Treatment
Adjuvant Therapy
MSKCC analysis of 1172 pts. Undergoing RO curativeresection
- 42% incidence of recurrent disease after long termfollow-up- 54% locoregional- 51% distant loci- 79% picked up w/in 2yrs.- median time of death 6 months
High likelyhood of recurrence has stimulated interestin combined modality therapies for resected gastriccancer
7/31/2019 Neoplastic Diseases of the Stomach
26/82
Combined Modality Treatment
Adjuvant chemotherapy +/- radiation has failed todemostrated benefit survival
However, adjuvant chemoradiation is suggested asstandard of care in US
Intergroup 0016 trial
- compared post-op 5-FU, leucovorin and external beamradiation to observation
- overall and disease free survival
- Flawed quality control
- Recommended D2 dissection (10% got it)
- 54% had less than D1 dissection
- Probably equal to outcomes of extensive LN dissection(>15LN)
7/31/2019 Neoplastic Diseases of the Stomach
27/82
Combined Modality Treatment
Neoadjuvant Therapy- Review of Intergroup 0116- only 64% were able to complete therapy
Potential benefits of pre-op chemotherapy
Oncologic benefit of chemo or chemorads controversial
MAGIC trial compared pre-op chemo to surgery alone- suggest resectability and more durable overallsurvival
- radiation not used
Parameters guiding appropriate selection of patientcurrently unavailable
7/31/2019 Neoplastic Diseases of the Stomach
28/82
Treatment guidelines
Management requires multidisciplinary approach(Medical, Surgical, Radiation Oncology, Nutritionist,Endocopist)
Workup
- Usually present with anemia, weight loss, N/V,and/or bleeding- H & P- CXR
- Upper endoscopy- CBC- CMP- CT +/- PET- EUS if potentially resectable H.Pylori testing
7/31/2019 Neoplastic Diseases of the Stomach
29/82
Treatment guidelines
Initial Workup classifies pts. Into 3 groups
Localized (Tis or T1a)
Locoregional (Stage 1-3)
- Medically fit w/potential for resection- Medically fit but unresectable- Medically unfit
Metastatic (Stage 4 or M1)
7/31/2019 Neoplastic Diseases of the Stomach
30/82
Treatment guidelines
Primary treatment
- EMR or surgery for medically fit (Tis or T1)
- Surgery for medically fit and T1b tumors
- Advancd tumors receive perioperative chemotherapy(Calss 1) or pre-op chemoradiation (Class 2B) for T2 andhigher tumors in medically fit
- RT (45-50.4Gy) with senstization or palliativechemotherapy for medically fit patient with unresectabledisease
- Medically unfit or fit with unresectable disease needrestaging after completion of therapy
If complee response, may be observed or offered surgery ifappropriate
7/31/2019 Neoplastic Diseases of the Stomach
31/82
Treatment guidelines
Post-op Treatment
- Based on surgical margins and nodalstatus
- Tis, T1NO, T2NO may be observed
- T2N0 with high risk features require
postop chemorads
- T3< require chemorads
7/31/2019 Neoplastic Diseases of the Stomach
32/82
Palliation
Bleeding endoscopy orangioembolization
Ostruction gastrojujunostomy,stenting, PEG
Pain- RT and pain meds
N/V - antiemetics
7/31/2019 Neoplastic Diseases of the Stomach
33/82
Hepatobiliary Cancer
- Anatomy- Epidemiology- Staging
- Surgery- CombinedModality Treatment- Treatment
Guidelines- Summary
7/31/2019 Neoplastic Diseases of the Stomach
34/82
Epidemiology
Hepatocellular Carcinoma
- most common hepatobiliary cancer
Risk factors
- Chronic Hepatitis B/Hepatitis C- hereditary hemochromatosis, porphyria cutanea tarda, alpha 1antitrypsin disorder
- autoimmune hepatitis
- Non-alcoholic fatty liver disease
- excessive alcohol intake
- aflatoxin
Most cases risk factor for HCC mimic risk factors for liver cirrhosis
7/31/2019 Neoplastic Diseases of the Stomach
35/82
Epidemiology
Screening for HCC
- AFP and liver U/S most widely used
- U/S alone is better than AFP alone
- Combined modalities better
At- risk populations
- periodic screening with U/S and AFP testing every 6-
12mo- Additional imaging (CT with contrast) recommendedwith AFP level or findings of liver mass nodule
7/31/2019 Neoplastic Diseases of the Stomach
36/82
Diagnosis and Work-up
HCC is asymptomatic for most of its course
Symptoms Usually nonspecific
- jaundice
- anorexia- malaise- upper abdominal pain
Signs
- Hepatomegaly- Ascites- Paraneoplastic syndromes (hyperlipidemia,Hypercalcemia, Hypoglycemia
7/31/2019 Neoplastic Diseases of the Stomach
37/82
Diagnosis and Workup
Imaging
- HCC lesions are hypervascular- Derive most of blood supply from hepatic artery- Triphasic helical CT- Trphasic cortrast MRI
Classic imaging profile is intense arterial uptake followed bycontrast washout or hypodensity in delayed phase
Pts w/liver mass on U/S should receive one or more imagingmodalities
- 1-2cm nodule needs two imaging modalities
- classic arterial enhancement in 2 modalities is considereddiagnostic of HCC
- Tissue sampling recommended when classic pattern not observedor seen with only one modality
7/31/2019 Neoplastic Diseases of the Stomach
38/82
Diagnosis and Workup
Biopsy- May not be required- Needle core biopsy (preferred) or FNA is recommended in somecases
FNA
- may have lower complication rate- rapid staining and examining samples- Highly dependent on operator skill- possible high false negative and false positive rates
NCB- more invasive- provides cytology and architecture
- additional histological tests may be performed
Use of biopsy is limited- nondiagnostic biopsies should be followed closely- change in size of a nodule warrants additional imaging or biopsy
7/31/2019 Neoplastic Diseases of the Stomach
39/82
Diagnosis and Workup
Initial Workup
- Multidisciplinary team
- Hepatitis panel
- Comorbidity assessment
- Imaging studies to look for mets.
- evaluation of Hepatic function and presence of portal HTN
Common sites of metastasis- Lung
- Abdominal LN
- Bone
7/31/2019 Neoplastic Diseases of the Stomach
40/82
Diagnosis and Workup
Chest Imaging and bone scan recommended as partof initial workup
Triphasic CT or MRI
- tumor burden
- metastatic disease
- vascular invasion
- portal HTN- size, location and estimate of liver remnant inrelation to total volume
7/31/2019 Neoplastic Diseases of the Stomach
41/82
Diagnosis and Workup
Liver function Testing
- serum bilirubin- AST/ALT- Alk Phos.- PT/PTT/INR- albumin- protein
Child-Pugh classification
- 3 classes according to likelihood of survival
7/31/2019 Neoplastic Diseases of the Stomach
42/82
7/31/2019 Neoplastic Diseases of the Stomach
43/82
Diagnosis and Workup
Model for End-Stage Liver Disease (MELD)
- numerical scale
- ranges from 6 (less ill) to 40 (gravely ill)
- sometimes used in place of Child-Pughclassification to asses prognosis in livercirrhosis
- used by UNOS for transplant waiting liststratification
7/31/2019 Neoplastic Diseases of the Stomach
44/82
7/31/2019 Neoplastic Diseases of the Stomach
45/82
Pathology
3 types of HCC identified
Nodular- associated with cirrhosis
- well circumscribed nodules
Massive- usally non-cirrhotic liver
- occupies large area- with or w/out satellitenodules
Diffuse- Less common- diffuse involvement of manysmall indistinct nodules
7/31/2019 Neoplastic Diseases of the Stomach
46/82
7/31/2019 Neoplastic Diseases of the Stomach
47/82
Management
Vascular invasion major predictor of outcome afterresection
Pt. with HCC must be carefully evaluated
- Underlying liver dz complicates management
- different types of HCC may impact tx. response
- Treatmentnecessitates involvement of large teams
(Hepatologist, IR, Transplant surgeons, pathologists,etc.)
7/31/2019 Neoplastic Diseases of the Stomach
48/82
Management
Partial Hepatectomy
- potentially curative in early stage HCC who are eligible- can be performed with low morbidity and mortality (5% orless)- some studies report 5yr survival over 50%
- 70% with good functional reserve- High incidence of recurrence- Careful patient selection is essential
Resection recommended only in setting of preserved liverfunction
- Child-Pugh score A- No portal HTN- Child-Pugh score B may be considered in selected cases(normal LFTs)
7/31/2019 Neoplastic Diseases of the Stomach
49/82
Management
Liver Transplantation
- attractive, potentially curative option for pts. Withearly HCC- removes detectable and undetectable LN
- treats cirrhosis- avoids complications associated with a small FLR- UNOS specify that candidates for transplant shouldnot be candidates for resection
Initial tx. Of choice in early HCC and moderate tosevere cirrhosis (Child class B and C)
7/31/2019 Neoplastic Diseases of the Stomach
50/82
Management
Local Regional Therapy directed at inducingselective tumor necrosis
Has not been established as comparable to transplantor hepatectomy
Alation- Chemical exposure (ethanol, acetic acid)- temperature (RFA, cryoablation, microwave)- can be performed laparascopically, open or
percutaneous- most common methods are RFA percutaneousethanol injection (PEI)- low complication rate (4% and 0%)
7/31/2019 Neoplastic Diseases of the Stomach
51/82
Management
Embolization
- based on tumor blood supply
- catheter based infusion of particles targeted to the branch ofhepatic artery feeding tumor
- Limited to segment, subsegment, or lobe
- all HCC tumors may be amenable to embolization provided thatthe blood supply may be isolated
- Unresectable/inoperable disease
- not amenable to ablation
- absence of extrahepatic disease
- >5cm, inoperable embolization, 3-5cm inoperable ablation +embolization
7/31/2019 Neoplastic Diseases of the Stomach
52/82
Management
Systemic therapy- Generally reserved forvery advanced liver disease
Usually only given to unresectable HCC inpresence of clinical trial
Sorafenib- recommended for Child Class A
- unresectable- not suitable for transplant- local disease only in pts non-operable
7/31/2019 Neoplastic Diseases of the Stomach
53/82
Surveillance
Cross sectional imaging every 3-6months for 2yrs, then annually
AFP levels if initially elevated shouldbe measured every 3mo for 2yrs,then every 6mo
Reevaluation undertaken forprogression or recurrence
7/31/2019 Neoplastic Diseases of the Stomach
54/82
Gallbladder cancer
Risk factors
- Gallstones
- chronicinflammation
- calcification(porcelaingallbladder)
7/31/2019 Neoplastic Diseases of the Stomach
55/82
Diagnosis and Workup
Often diagnosed at advanced stage
- aggressive tumor
- clinical presentation mimics biliary colic or chronic cholecystitis
- Often dx. as incidental finding at surgery or on pathology review
following cholecystectomy
Workup of suspicious mass on U/S or jaundice
- LFTs, evaluation of hepatic reserve- CEA Ca 19-9 (not specific)- CT abdomen to assess extent and nodal disease
- Chest XR or CT- Cholangiography (MRCP preferred over ERCP or PTC unlessintervention planned)
7/31/2019 Neoplastic Diseases of the Stomach
56/82
Pathology and Staging
80% adenocarcinomas
- often have earlyspread to lymph nodes
and bloodstream
Poor prognosis
- 5yr survival 39%stage 1
- 1% stage 4
7/31/2019 Neoplastic Diseases of the Stomach
57/82
7/31/2019 Neoplastic Diseases of the Stomach
58/82
Management
Surgery only curative modality
All pts. needCT/MRI and chest imaging prior tosurgery
Staging laparoscopy should beconsidered prior tolaparotomy
Recommended surgery for known diagnosis
- cholecystectomy
- en-bloc hepatic resection- lymphadenectomy with or without bile duct excision- Portahepatis,retroduodenal, gastrohepatic ligament- Nodal disease outside of this area is unresectable
7/31/2019 Neoplastic Diseases of the Stomach
59/82
Management
Surgery for tumor detected after cholecystectomy
- 74% found to have residual dz during reexploration
- Recommend extended cholecystectomy
- T1a may be observed (no muscle involvement)
- T1b or greater require metastatic workup, then hepatic resectionand lymphadenectomy
- Should not be performed by inexperienced surgeon or unknownresectability
Unresectable disease- biopsy to confirm diagnosis- biliary drainage- possible chemotherapy or chemoradiation (usually in clinical trial)- supportive care
7/31/2019 Neoplastic Diseases of the Stomach
60/82
Cholangiocarcinoma
Tumors originating from epithelium of bile duct
Distinguished by anatomic site
Intrahepatic
- peripheral cholagiocarcinomas- located within hepatic parenchyma
Extrahepatic
- hilar cholangiocarcinomas(Klatskins tumors)- usually near junction of left and right hepatic ducts- more common- hilar is most common type
7/31/2019 Neoplastic Diseases of the Stomach
61/82
Cholangiocarcinoma
Risk factors
- No predisposing factors have been identified in mostpatients
- May be associated with chronic inflammation
- chronic calculi
- Primary sclerosis cholangitis
- Choledochal cysts
- liver fluke infections
- gallstones not related
- Hep C may be associated with intrahepatic forms
7/31/2019 Neoplastic Diseases of the Stomach
62/82
Diagnosis and workup
Typically asymptomatic
Intrahepatic likely to present with
- fever- weight loss- abdominal pain- biliary obstruction uncommon- may be detected as isolated intrahepatic mass onimaging
Extrhepatic likely to present with- jaundice followed by obstruction
7/31/2019 Neoplastic Diseases of the Stomach
63/82
Diagnosis and Workup
Workup
- LFTs
- CEA and Ca 19-9 (not specific)- Delayed contrast CT/MR (helpful indetermining resectability)
- Chest imaging- Cholangiography in patients with jaundice(MRCP vs. ERCP vs. PTC)
7/31/2019 Neoplastic Diseases of the Stomach
64/82
Pathology and staging
>90%adenocarcinomas
Divided into 3types
- Mass forming
- periductal
- intraductal
7/31/2019 Neoplastic Diseases of the Stomach
65/82
7/31/2019 Neoplastic Diseases of the Stomach
66/82
7/31/2019 Neoplastic Diseases of the Stomach
67/82
Management
Intrahepatic cholangiocarcinoma- Complete resection on curative modality- most pts. Not candidates for surgery due to advanced dz. Atpresentation
Surgery involves removing entire lobe or segment along theinvolved duct
R0 resetion associated with longer survival rates
20-43% 5yr survival
R0 resections may be observed
R1 or R2 need individualized therapy
Unresectable disease chemo, chemorads, clinical trial, supportivecare
7/31/2019 Neoplastic Diseases of the Stomach
68/82
Management
Extrahepatic cholangiocarcinomas
- complete resction main curative strategy
Surgical procedure based on location- Proximal 1/3 hilar resection with lymphadenectomy and en-blocliver resection- Mid 1/3 major bile duct excision with lymphadenectomy,assessment of margins- Distal 1/3 Pancreaticoduodenectomy
R0 resection may be observed, chemo, or chemorads (nostandard)
Liver transplant only other possible curative modality forextrahepatic cholangiocarcinoma
- unresectable dz.- normal biliary function
7/31/2019 Neoplastic Diseases of the Stomach
69/82
Management
Distal strictures- ERCP with brushing and stenting
Unresectable disease- biliary drainage (PTC or ERCP +stent)- biopsy- clinical trial, chemo, or chemorads (no
standard)
Metastatic disease as above
7/31/2019 Neoplastic Diseases of the Stomach
70/82
Surveillance
No data to support aggressive surveillance
Imaging every 6mo to 2yrs
Although most pts. With hepatobiliarycancers found at advanced stage, all shouldbe evaluated for treatment
Careful selection and multidisciplinaryapproach are essential
7/31/2019 Neoplastic Diseases of the Stomach
71/82
Pancreatic Adenocarcinoma
36,800 die eachyear
4th MCC death inUS men andwomen
Peak incidence 7thand 8th decades
African Americanhave higherincidence thanwhites
7/31/2019 Neoplastic Diseases of the Stomach
72/82
Anatomy
7/31/2019 Neoplastic Diseases of the Stomach
73/82
Pancreatic adenocarcinoma
Risk factors
- Cigarette smoking
- Increased BMI
- incresed meat and dairy products
- occupational exposure to chemicals(benzidine andbetanaphthylamine)
- chronic pancreatitis
- alcohol intake
7/31/2019 Neoplastic Diseases of the Stomach
74/82
Pancreatic adenocarcinoma
Familial pancreatic cancer is rare
- 5-10% may have genetic
predisposition
- May be associated with BRCA2
mutations
- Assess family history
7/31/2019 Neoplastic Diseases of the Stomach
75/82
Diagnosing and staging
Ductal adenocarcinoma >90% of pancreatic malignancies
Presenting symptoms- weight loss- jaundice- floating stools- pain
- dyspepsia- nausea- depression
No early warning signs
May be considered in diabetics presentin>50 or with unusual
manifestations
Pts. Should undergo helical or spiral CT with pancreatic protocol ifpancreatic cancer is suspected
7/31/2019 Neoplastic Diseases of the Stomach
76/82
Imaging
CT best and most widely used
- Triphasic (arterial, late arterial, venous)
- Thin slices
Helps to distinguish resectable vs. unresectable
CT is primary means through which stage is determined
70-85% determined to have resectable tumors by CT were able toundergo resection (specificity > sensitivity)
MRI may be sued if CT isnt possible
EUS is complementary to CT
Chest imaging
7/31/2019 Neoplastic Diseases of the Stomach
77/82
Laparoscopy is a a valuable staging tool may pick up implants missed by CT
Tumor antigens
- Ca 19-9 should be performed afterbiliary decompression
- low postop Ca 19-9 levels and declininglevels ater surgery are associated withimproved survival
7/31/2019 Neoplastic Diseases of the Stomach
78/82
Staging and resectability
Patients with stage 0, 1, or 2 are generallyconsidered resectable
Some surgeons will resect patients withstage 3 tumors
Pts. With tumor confined to the pancreas
and resected LN w/o vascular invasion arecandidates for surgery
7/31/2019 Neoplastic Diseases of the Stomach
79/82
7/31/2019 Neoplastic Diseases of the Stomach
80/82
Chemoradiation
Neoadjuvant therapy is not routinelyperformed- may be used in locally invasive
disease- 10% downstaging
Adjuvant therapy is the standard ofcare with chemotherapy +/- radiation
7/31/2019 Neoplastic Diseases of the Stomach
81/82
Surgery
Pancreaticoduodenectomy is treatment
- delayed gastric emptying in 15%
Postop chemotherapy is given
Palliation may involve biliary drainage forrecurrent or metastatic disease
Sympathetic denervation may beperformed for intractable pain
7/31/2019 Neoplastic Diseases of the Stomach
82/82
References
NCCN guidelines
Cameron